SZSusan M. Zbikowski

Susan M. Zbikowski

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Susan M. Zbikowski has a total of 22 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Utilization of Services in a Randomized Trial Testing Phone- and Web-Based Interventions for Smoking Cessation

    by Susan M. Zbikowski, Lisa M. Jack, Jennifer B. McClure, Mona Deprey, Harold S. Javitz, Timothy A. McAfee, Sheryl L. Catz, Julie Richards, Terry Bush, Gary E. Swan

    Phone counseling has become standard for behavioral smoking cessation treatment. Newer options include Web and integrated phone–Web treatment. No prior research, to our knowledge, has systematically compared the effectiveness of these three treatment modalities in a randomized trial. Understanding how utilization varies by mode, the impact of utilization on outcomes, and predictors of utilization across each mode could lead to improved treatments. One thousand two hundred and two participants were randomized to phone, Web, or combined phone–Web cessation treatment. Services varied by modality and were tracked using automated systems. All participants received 12 weeks of varenicline, printed guides, an orientation call, and access to a phone supportline. Self-report data were collected at baseline and 6-month follow-up. Overall, participants utilized phone services more often than the Web-based services. Among treatment groups with Web access, a significant proportion logged in only once (37% phone–Web, 41% Web), and those in the phone–Web group logged in less often than those in the Web group (mean = 2.4 vs. 3.7, p = .0001). Use of the phone also was correlated with increased use of the Web. In multivariate analyses, greater use of the phone- or Web-based services was associated with higher cessation rates. Finally, older age and the belief that certain treatments could improve success were consistent predictors of greater utilization across groups. Other predictors varied by treatment group. Opportunities for enhancing treatment utilization exist, particularly for Web-based programs. Increasing utilization more broadly could result in better overall treatment effectiveness for all intervention modalities.


  • Open Access

    Phone and Web-Based Tobacco Cessation Treatment: Real-World Utilization Patterns and Outcomes for 11,000 Tobacco Users

    by Susan M Zbikowski, Jenny Hapgood, Sara Smucker Barnwell, Tim McAfee

    Phone and Web-Based Tobacco Cessation Treatment: Real-World Utilization Patterns and Outcomes for 11,000 Tobacco Users


    • 1 March 2004
      • Vol. 10  (3) , 217-26

    Cost-effectiveness of different combinations of bupropion SR dose and behavioral treatment for smoking cessation: a societal perspective.

    by Harold S Javitz, Gary E Swan, Susan M Zbikowski, Susan J Curry, Timothy A McAfee, Donna L Decker, Richard Patterson, Lisa M Jack

    To determine the differential cost effectiveness of 2 dosing regimens of bupropion sustained release (SR) in combination with behavioral interventions of minimal intensity (tailored mailings [TM]) or moderate intensity (proactive telephone calls [PTC]) for smoking cessation in an actual practice setting. Open-label, randomized trial, with 1-year follow-up, conducted in a large health system based in Seattle, Washington. A total of 1524 adult smokers interested in quitting smoking were randomly assigned to receive 150 mg bupropion SR daily and PTC (n = 382), 150 mg bupropion SR daily and TM (n = 381), 300 mg bupropion SR daily and PTC (n = 383), or 300 mg bupropion SR daily and TM (n = 378). Sufficient medication for 8 weeks of dosing was provided to patients. The primary outcome measure was self-reported point-prevalence 7-day nonsmoking status at 12 months after the target quit date. Although the 300-mg dose was associated with a higher 12-month nonsmoking rate relative to the 150-mg dose with both PTC and TM, the additional cost resulted in lower cost effectiveness. The PTC behavioral intervention was more expensive than TM, but the additional effectiveness resulted in almost equivalent cost effectiveness at the 150-mg dose. Costs per additional 12-month nonsmoker (above that expected for placebo) for the 150-mg dose groups averaged 950 dollars and per additional lifetime quitter averaged 1508 dollars; for the 300-mg groups these costs were 1342 dollars and 2129 dollars, respectively. Cost per life-year and quality-adjusted life-years (QALYs) saved varied substantially by age and treatment, but were no greater than 1100 dollars for all treatment groups when averaged across the age and sex distribution for the study population. Although the cost per life-year and QALYs saved were sufficiently low for all doses to rate these smoking cessation interventions as among the most cost effective of life-saving medical treatments, within the regimens tested 150 mg bupropion combined with either PTC or TM was the most cost effective.


    • 1 March 2004
      • Vol. 29  (1) , 18-23

    Preventing premature death: tobacco treatment services for employees.

    by Tim McAfee, Dana Montanari, Sara Tifft, Susan M Zbikowski

    This article presents a summary of current information concerning the health and financial costs of workplace smoking, with special emphasis on the costs to union workers and multiemployer health and welfare funds. It describes the potential savings from investing in tobacco cessation for workers and members, provides an overview of scientific evidence concerning the efficacy of different approaches to tobacco cessation, including behavioral services and medications, and discusses some of the benefit design and management issues involved in offering tobacco cessation services to employees and members.